Ultimate Frozen House Playset ❄️ Elsa Mermaid Bath, Bathroom Setup & Cle... youtu.be/9XfY2jzSEkc?is=4YoG… via @YouTubemhuxxxcxxxx
101
📢 NEW in @BloodCancerJ! 360 RRMM pts on talquetamab: EMD had preserved ORR (68%) but shorter PFS (4.3 vs 7.8 mo). EMD: significant univariate but not multivariable—outcomes driven by tumor biology (↑LDH,↑ferritin) not anatomy. nature.com/articles/s41408-0…
For a comprehensive review on EMD in myeloma — biology, diagnosis, and treatment — check out our recent review in @CancersMDPI
mdpi.com/2072-6694/18/15/241… @staasan_MD @UTSWInternalMed @utswcancer @UTSWHemeOnc
1
3
96
We previously showed that #EMD is a poor prognostic factor with #Teclistamab (ORR 38%, PFS 1.4 mo vs 8.9 mo in no-soft-tissue plasmacytoma). Together, these studies reinforce the need for refined strategies in this high-risk population. nature.com/articles/s41408-0…
Take-home message: #Talquetamab has meaningful activity in #EMD, but better strategies are needed. Rational combinations (multiple targets, T-cell modulators (CELMoDs, etc)) and optimized supportive care may help improve outcomes
2
87
Aimaz Afrough retweeted
Grt ECOG ACRIN MM meeting with many trial concepts presented, brainstormed @eaonc
-new ideas
-challenges in trial design
-accrual challenges
- met colleagues and exhchanged grt ideas
@VincentRK @myelomaMD @NorthTxMSG @natashaedwin @nsc_natalie @JKaufmanMD @SagarLonialMD
Aimaz Afrough retweeted
#ASH25 not many investigator meetings look like this, but the @CoMMitTrials meeting thanks to @End_myeloma!
🍷 not shown, nor the 🛩️ Luciano has earned.
Look for many innovative trial results coming soon, including MASTER-2 with MRD-guided decision-making!
Aimaz Afrough retweeted
#ASH25 @ASH_hematology
Meeting fellowship family @BCMHemeOnc @bcmhouston
@Sarasinh @AimazAfrough @mahrefat @marthamims
Lots of myeloma in one pic #mmsm
Aimaz Afrough retweeted
#mmsm #ASH25 🙏 to all members of the US MM immunotherapy consortium
@StanfordDeptMed @StanfordBMT_CT @MoffittNews @VincentRK @End_myeloma @OmarNadeemMD @cjferreriMD @ldandersonjr @AimazAfrough
Aimaz Afrough retweeted
Study now open @UTSWMedCenter. Patients newly diagnosed with MM in the Dallas area can receive personalized response-adapted treatment with the wonderful @ldandersonjr @AimazAfrough @HealthTree #MMSM @utswcancer
Newly diagnosed with MM? MASTER-2 addressed response adapted therapy with the perspective of finite treatment. Accruing fast! #mmsm
Aimaz Afrough retweeted
#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/3996…. #mmsm
Aimaz Afrough retweeted
#Myeloma Paper of the Day: Whole genome sequencing of extramedullary disease in myeloma finds BRAF, NRAS, KRAS & MYC frequently implicated oncogenes, w/ frequent loss of tumor suppressor genes SP140 & TENT5C, suggesting central role of MAPK pathway: pubmed.ncbi.nlm.nih.gov/3979…. #mmsm
Aimaz Afrough retweeted
Why? Excellent #IMS24 plenary by Machlachlan @MSKCancerCenter 👇
PMD and EMD look very different at a genomic level, and we should stop conflating them.
Kudos to many junior faculty @ZanwarSaurabh @DimaDanai @AimazAfrough @DarrenPanMD et al who’ve helped show this clinically!
Aimaz Afrough retweeted
CONGRESS | #IMS2024 | PRESENTATION
Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709), which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and consolidation therapy and to lenalidomide maintenance therapy for transplant eligible (TE) patients with NDMM.
This analysis confirmed the favorable PFS benefits and demonstrated the higher rates of deep and sustained MRD negativity with the addition of D to VRd induction and R maintenance, supporting the use of D-VRd induction/consolidation followed by D-R maintenance as a new SOC for TE NDMM.
Follow our live feed for more updates: multiplemyelomahub.com/medic…
#mmsm #myeloma #MedicalCongress
Aimaz Afrough retweeted
#IMS24 the US #MMsm immunotherapy consortium is growing and I could not be happier to see it!
@SurbhiSidanaMD @DrKrinaPatel @bhemato @PlasmaCellPete @ldandersonjr @BiranNoa @khouri_jack @AimazAfrough - missing @AlGarfall @GKaurMD and many more!
Best meeting of #IMS24! Thanks @SurbhiSidanaMD @DrKrinaPatel #dorishansen for leading this endeavor and so many sub-projects 🙏
Cc @PlasmaCellPete @ldandersonjr @AimazAfrough @BiranNoa and many more!
Aimaz Afrough retweeted
Join us and @ASTCT for our Physician Exchange at #SOHO2024! Hear from our panel of experts on the latest in #MDS research, clinical trials and transplant insights—plus earn 1.0 CME credit!
📅 Sept. 4 | 11:46 a.m.
📍 GRB Convention Center | Room 350F
🔗 bit.ly/4dFAtp6
Aimaz Afrough retweeted
Instagram Post
📢 Big News!
We are thrilled to announce that @SuzanneColeMD has been selected as one of the recipients of the 2023-2024 IM UME Outstanding Faculty Teaching Award! 🏆✨
@UTSWInternalMed @utswcancer
